Durable medical equipment (DME) compliance has long been fertile ground for government scrutiny, but bone growth stimulators present a particularly nuanced—and risky—intersection of reimbursement rules, medical necessity, and marketing practices. A review of enforcement actions, civil litigation, and regulatory guidance reveals recurring compliance failures that should be top of mind for compliance officers overseeing providers, DME suppliers, manufacturers, and clinical relationships.